282 related articles for article (PubMed ID: 37295816)
1. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
[TBL] [Abstract][Full Text] [Related]
2. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
3. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Juluri KR; Wu QV; Voutsinas J; Hou J; Hirayama AV; Mullane E; Miles N; Maloney DG; Turtle CJ; Bar M; Gauthier J
Blood Adv; 2022 Apr; 6(7):2055-2068. PubMed ID: 34666344
[TBL] [Abstract][Full Text] [Related]
4. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
Lichtenstein DA; Schischlik F; Shao L; Steinberg SM; Yates B; Wang HW; Wang Y; Inglefield J; Dulau-Florea A; Ceppi F; Hermida LC; Stringaris K; Dunham K; Homan P; Jailwala P; Mirazee J; Robinson W; Chisholm KM; Yuan C; Stetler-Stevenson M; Ombrello AK; Jin J; Fry TJ; Taylor N; Highfill SL; Jin P; Gardner RA; Shalabi H; Ruppin E; Stroncek DF; Shah NN
Blood; 2021 Dec; 138(24):2469-2484. PubMed ID: 34525183
[TBL] [Abstract][Full Text] [Related]
5. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
[TBL] [Abstract][Full Text] [Related]
6. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
9. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
10. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells.
Galli E; Sorà F; Hohaus S; Fresa A; Pansini I; Autore F; Metafuni E; Innocenti I; Limongiello MA; Giammarco S; Laurenti L; Bacigalupo A; Chiusolo P; De Stefano V; Sica S
Br J Haematol; 2023 Apr; 201(1):86-94. PubMed ID: 36503182
[TBL] [Abstract][Full Text] [Related]
11. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials.
Silbert SK; Madan S; Holland EM; Steinberg SM; Little L; Foley T; Epstein M; Sarkisian A; Lee DW; Nikitina E; Kakumanu S; Ruppin E; Shalabi H; Yates B; Shah NN
Blood Adv; 2023 Sep; 7(18):5566-5578. PubMed ID: 37486616
[TBL] [Abstract][Full Text] [Related]
14. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis.
Li L; Wang L; Liu Q; Wu Z; Zhang Y; Xia R
Front Oncol; 2022; 12():954345. PubMed ID: 36644638
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
17. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Fergusson NJ; Adeel K; Kekre N; Atkins H; Hay KA
Front Immunol; 2023; 14():1178403. PubMed ID: 37180149
[TBL] [Abstract][Full Text] [Related]
19. A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.
Zhang Y; Li S; Wang Y; Lu Y; Xu Y; Rao Q; Wang H; Xing H; Tian Z; Tang K; Lv L; Wang M; Wang J
Exp Hematol Oncol; 2022 Mar; 11(1):15. PubMed ID: 35317863
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
